在阿尔茨海默病中的功能性脊髓肌:巧合还是新的挑战?
Enrico Bergamin1, F Turco2, E Unti3
1Department of Clinical and Experimental Medicine, Neurology Unit, University of Pisa, Pisa, Italy. enricobergaminmd@gmail.com.
概括
功能性PSM是一种运动障碍,可以与阿尔茨海默病同时发生. 这一案例凸显了在神经退行性疾病中识别功能神经障碍对于准确诊断和治疗的重要性.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 运动障碍 运动障碍
背景情况:
- 脊髓肌 (PSM) 是一种罕见的高动力运动障碍.
- 传统上被归类为特异性或症状性,PSM通常具有功能性病因.
- 功能神经系统障碍 (FNDs) 涉及与有机神经系统疾病不一致的症状,与大脑电路功能障碍有关.
研究的目的:
- 报告阿尔茨海默病 (AD) 患者中第一个功能性PSM病例.
- 在这种共存条件下研究电生理学生物标志物的诊断实用性.
- 强调综合诊断和治疗方法的必要性.
主要方法:
- 一个61岁的阿尔茨海默氏症妇女的病例报告显示,她患有功能性PSM.
- 电生理学评估包括Bereitschaftspotential (BP) 和与事件相关的脱同步 (ERD).
- 评估运动症状,焦虑,以及对分心和塞特拉林治疗的反应.
主要成果:
- 患者出现了无意识的干运动,焦虑和不安,这些都通过分心而消失.
- 电生理学评估显示ERD没有BP,支持功能诊断.
- 塞特拉林治疗导致了运动症状和焦虑的改善.
结论:
- 功能性PSM可以与AD等神经退行性疾病共存,这表明共享的病理生理机制.
- 像ERD这样的电生理学生物标志物对于诊断功能性PSM非常有价值.
- 在神经退行性疾病中识别FND对于准确的诊断和改善患者结果至关重要.
关键词:
阿尔茨海默氏症 (AD) 是一种疾病.准备能力潜力 (BP) 是指准备能力潜力.与事件相关的脱同步 (ERD)功能神经系统疾病 (FNDs) 是一种功能性神经系统疾病.自己的脊柱肌 (PSM)更多相关视频
相关概念视频
Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Alzheimer's Disease: Treatment
736
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
736
Parkinson's Disease: Treatment
931
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
931
Myasthenia Gravis: Diagnostic Tests
1.8K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.8K


